New drug selinexor tested in kids with Tough-to-Treat leukemia
NCT ID NCT02091245
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing the drug selinexor (KPT-330) in 16 children and young adults with leukemia that has come back or not responded to standard treatments. The main goal is to find the safest dose and understand side effects. The drug works by blocking a protein that leukemia cells need to survive, potentially killing them.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Selinexor (KPT-330)
What this could lead to
If it works, this could point toward a new treatment option for children with leukemia that has not responded to standard therapies.
What could go wrong
This is a very early phase 1 trial with only 16 participants, so it is primarily testing safety and dosing. The drug may not effectively control the leukemia, and side effects could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Children's Healthcare of Atlanta
Atlanta, Georgia, 30322, United States
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Seattle Children's Hospital
Seattle, Washington, 98101, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
-
UCSF
San Francisco, California, 94143, United States